Lactobacillus johnsonii capable of relieving obesity and application of lactobacillus johnsonii

The Lactobacillus johnsonii LJ-XR25 strain addresses the inefficacies of current probiotics by reducing weight and fat, regulating lipid metabolism, and restoring intestinal balance, offering a promising solution for obesity treatment.

CN119060886AInactive Publication Date: 2024-12-03HENAN UNIV OF CHINESE MEDICINE

Patent Information

Application Number
CN202411181601.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-27
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing technologies fail to provide a probiotic strain with satisfactory effects on alleviating obesity and regulating lipid metabolism, as current strains exhibit unsatisfactory efficacy and unclear action relationships.

Method used

A Lactobacillus johnsonii strain, LJ-XR25, isolated from obese mouse models treated with traditional Chinese medicine essential oils, is identified and deposited, which significantly reduces weight and fat content, regulates lipid metabolism, and restores intestinal flora balance.

Benefits of technology

Lactobacillus johnsonii LJ-XR25 effectively reduces weight and fat, improves lipid metabolism, and restores intestinal ecology, demonstrating significant potential in preventing and treating obesity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060886A_ABST
    Figure CN119060886A_ABST
Patent Text Reader

Abstract

The invention provides lactobacillus johnsonii capable of relieving obesity and application of the lactobacillus johnsonii, and relates to the technical field of microorganisms and the technical field of biological medicines. The lactobacillus johnsonii LJ-XR25 is separated from excrement of an obesity model mouse treated by gynostemma pentaphyllum essential oil, and the preservation number is GDMCC NO: 65011. The LJ-XR25 provided by the invention can obviously reduce the weight and fat content of an obese mouse model; the traditional Chinese medicine composition has the functions of improving hyperlipidemia symptoms of high-fat diet mice, improving the antioxidant capacity of livers, transporting phospholipids and cholesterol, eliminating cholesterol of peripheral blood vessels and regulating lipid metabolism; meanwhile, the LJ-XR25 can be colonized in the intestinal tract, so that the diversity of intestinal flora is increased, the effect of repairing the intestinal flora disorder caused by high-fat diet is achieved, and the ecological balance of the intestinal tract is restored. The LJ-XR25 provided by the invention can be used for preparing products such as food, medicines, microbial preparations or feed additives for preventing and / or relieving and / or improving and / or treating obesity, and has wide application value and practical significance.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of microorganisms and biomedicine, and in particular to a Lactobacillus johnsonii capable of alleviating obesity and an application thereof. Background Art

[0002] Probiotics are often considered to be a type of microorganism that has beneficial effects on the human body and animals, including bifidobacteria, lactic acid bacteria, lactobacillus, lactococci, enterococci, and the second-generation probiotics proposed in recent years. They can colonize the intestines of animals, improve microbial balance, help absorb vitamins, etc. The secondary bile acids, short-chain fatty acids and other factors produced by some probiotics after intervening in the body can improve the intestinal ecology, thereby showing antioxidant, anti-inflammatory, hypoglycemic and lipid-lowering, and anti-tumor effects, affecting the occurrence and development of diseases.

[0003] In recent years, with the rapid development of China's social economy and the continuous improvement of people's living standards, the problem of overweight and obesity in China has become more and more serious. The "Guidelines for Dietary Treatment of Adult Obesity (2024 Edition)" shows that the overweight and obesity rates of residents aged 18 and above in my country have reached 34.3% and 16.4%, and the obesity rate of residents is on the rise. Overweight and obesity have become an important public health issue affecting the health of the people. What is more worrying is that this trend is prevalent among people of different ages, genders and regions, and is gradually getting younger. Overweight and obese patients have a wide distribution of visceral and surface fat, and excessive accumulation of triglycerides (TG) in tissue serum leads to obesity and mild inflammation of the liver, which not only affects the individual's physical health and increases the risk of various chronic diseases, such as diabetes, stroke, coronary artery disease, hypertension, respiratory diseases, obstructive sleep apnea, osteoarthritis and gallstones, but also brings a huge economic burden to society. my country's National Health Commission and 16 other departments have jointly launched the "Weight Management Year" campaign and formulated the "Weight Management Year" Activity Implementation Plan. Starting from 2024, they strive to achieve significant improvement in the awareness and skills of weight management among the entire population in about three years, and improve the abnormal weight conditions of some groups of people. This is enough to show that the country is gradually paying attention to metabolic diseases such as overweight / obesity.

[0004] At present, researchers have begun to try to use probiotic preparations to treat obesity and regulate the body's lipid metabolism. Probiotic preparations are safe and healthy for the human body, and the administration method is simple. Representative probiotics include Lactobacillus and Bifidobacterium. The genus Lactobacillus is a complex classification consisting of more than 170 species. Lactobacillus can be implanted in multiple areas of the human body, the most important of which is the digestive tract, and the rest include the oral cavity and the female reproductive tract. The association between Lactobacillus and humans is a mutualistic relationship that can help the host digest dietary substrates and protect against pathogens. It is one of the most common probiotics. The main types of lactobacillus currently on the market include: Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus bulgaricus subspecies, Lactobacillus gasseri, Lactobacillus helveticus, Lactobacillus johnsonii, Lactobacillus paracasei subspecies, Lactobacillus plantarum, Lactobacillus reuteri and Lactobacillus rhamnosus. However, there is evidence that many characteristics of these probiotics depend on species and strains, and the above-mentioned strains have defects such as unsatisfactory effects on alleviating obesity and regulating lipid metabolism or unclear action relationships. Therefore, it is necessary to continue the isolation and identification of probiotic strains and the study of their probiotic functions. It is very necessary to seek a new strain that is highly targeted at obesity, has a strong ability to alleviate obesity, and has a clear regulatory effect on lipid metabolism, and to develop its application. Summary of the invention

[0005] 1. Technical issues to be resolved

[0006] In view of the deficiencies of the prior art, the present invention provides a Lactobacillus johnsonii having the effects of alleviating obesity and regulating lipid metabolism.

[0007] (II) Technical solution

[0008] To achieve the above objectives, the present invention is implemented through the following technical solutions:

[0009] In a first aspect, the present invention provides a Lactobacillus johnsonii LJ-XR25, wherein the Lactobacillus johnsonii LJ-XR25 belongs to the genus Lactobacillus, has been deposited in the Guangdong Provincial Microbiological Culture Collection Center, the preservation date is August 15, 2024, and the preservation number is GDMCC NO:65011.

[0010] Specifically, the Lactobacillus johnsonii LJ-XR25 is derived from the feces of a small number of obese models treated with traditional Chinese medicine essential oils. After analysis, the 16S rDNA sequence of the strain is as shown in SEQ ID NO.1; the strain is Gram-positive, the colony color is mostly white or milky white, the edges are neat, and the morphology is long rod or short rod under a high-power microscope, and there is no budding reproduction.

[0011] In a second aspect, the present invention provides a microbial preparation containing Lactobacillus johnsonii LJ-XR25.

[0012] Specifically, the viable count of Lactobacillus johnsonii LJ-XR25 in the microbial preparation is not less than 1×10 9 CFU / mL.

[0013] Specifically, the dosage form of the microbial preparation includes powder, capsule, tablet or granule.

[0014] In a third aspect, the present invention provides the use of Lactobacillus johnsonii LJ-XR25 in the preparation of a product for preventing and / or improving and / or alleviating and / or treating obesity.

[0015] In a fourth aspect, the present invention provides the use of Lactobacillus johnsonii LJ-XR25 in the preparation of a product for inhibiting weight gain.

[0016] In a fifth aspect, the present invention provides the use of Lactobacillus johnsonii LJ-XR25 in the preparation of a product that inhibits lipid production genes FASN and / or PPAR-R and / or SCD-1.

[0017] In a sixth aspect, the present invention provides the use of Lactobacillus johnsonii LJ-XR25 in the preparation of a product for regulating intestinal symbiotic flora.

[0018] In the above applications, the products include but are not limited to microbial preparations, ordinary foods, special foods, medicines, and feed additives.

[0019] In the above application, the product also contains auxiliary materials, which include but are not limited to excipients or additives.

[0020] In the above application, the viable count of Lactobacillus johnsonii LJ-XR25 in the product is not less than 1×10 9 CFU / mL.

[0021] (III) Beneficial effects

[0022] The present invention isolates Lactobacillus johnsonii LJ-XR25 from feces of obese model mice treated with Gynostemma pentaphyllum essential oil, identifies it as Lactobacillus by 16S rDNA sequence, and has been deposited in Guangdong Microbiological Collection Center (GDMCC for short, address: Institute of Microbiology, Guangdong Academy of Sciences, Building 59, No. 100, Xianlie Middle Road, Yuexiu District, Guangzhou), with a preservation date of August 15, 2024 and a preservation number of GDMCC NO: 65011.

[0023] The Lactobacillus johnsonii LJ-XR25 provided by the present invention can significantly reduce the weight of obese mouse models, and significantly reduce the fat content in the groin, perirenal and epididymis of obese mice; it can effectively reduce the blood sugar, triglycerides and free fatty acids and fatty liver AST and ALT levels of obese mice, improve the hyperlipidemia symptoms of mice on a high-fat diet, improve the antioxidant capacity of the liver and the ability to transport phospholipids and cholesterol, and eliminate cholesterol in peripheral blood vessels, and achieve the function of regulating lipid metabolism; at the same time, Lactobacillus johnsonii LJ-XR25 can be colonized in the intestine, increase the diversity of intestinal flora, achieve the effect of repairing the intestinal flora disorder caused by a high-fat diet, and restore the ecological balance of the intestine. The Lactobacillus johnsonii LJ-XR25 provided by the present invention can be effectively used to prepare products such as food, medicine, microbial preparation or feed additive for preventing and / or alleviating and / or improving and / or treating obesity, and has broad application value and practical significance. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 Results of body weight and fat weight of two groups of mice; a, body weight of two groups of mice; b, body weight growth rate of two groups of mice; c, epididymal fat weight; d, inguinal fat weight; e, perirenal fat weight; compared with HFD group, *p<0.05, **p<0.01.

[0025] Figure 2 The results of HE sections of liver fat counts of two groups of mice.

[0026] Figure 3 Results of fat metabolism-related factors in serum and liver of two groups of mice; a, TG content in serum; b, TC content in serum; c, HDL-c content in serum; d, LDL-c content in serum; e, GSH content in liver tissue; f, TG content in liver tissue; g, GSH content in liver tissue; compared with the HFD group, *p<0.05, **p<0.01.

[0027] Figure 4 The expression results of genes related to liver fat metabolism in the two groups of mice; compared with the HFD group, *p<0.05, **p<0.01.

[0028] Figure 5 The structural changes of intestinal flora in two groups of mice. DETAILED DESCRIPTION

[0029] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below in combination with the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0030] Example 1

[0031] Isolation, cultivation and identification of bacterial species

[0032] Lactobacillus johnsonii LJ-XR25 was isolated from the intestinal feces of a small number of obese models after treatment with the traditional Chinese medicine Jiaogulan essential oil. It was identified as Lactobacillus by 16S rDNA sequence and has been deposited in the Guangdong Provincial Microbiological Collection Center (GDMCC for short, address: Institute of Microbiology, Guangdong Academy of Sciences, Building 59, No. 100, Xianlie Middle Road, Yuexiu District, Guangzhou). The preservation date is August 15, 2024, and the preservation number is GDMCC NO:65011.

[0033] Lactobacillus johnsonii LJ-XR25 was inoculated into MRS solid culture medium and cultured at 37°C for 48 hours. The colonies were observed and Gram staining was positive. The colonies were mostly white or milky white in color with neat edges. Under a high-power microscope, they had long rods and short rods in shape, and there was no budding reproduction.

[0034] 16S rDNA sequence of strain LJ-XR2 of the present invention 16S rDNA identification: using bacterial 16S rDNA universal primers (27F5'-AGAGTTTGATCCTGGCTCAG-3' and 1492R 5'-GGTTACCTTGTTACGACTT-3'), using the genome of strain LJ-XR2 as a template, PCR amplification was performed, and the amplified product was sequenced. Its sequence is shown in SEQ ID No.1; the sequencing results were sequenced on the NCBI website (https: / / blast.ncbi.nlm.nih.gov / Blast.cgi). The homology is 100% with Lactobacillus johnsonii, MK929073.1.

[0035] SEQ ID No.1

[0036]

[0037] Example 2

[0038] Effects of Lactobacillus johnsonii LJ-XR25 on obese mice

[0039] 1 Experimental animals

[0040] C57 / Bl6J mice were of standard strain, 7 weeks old, weighing (20±1) g, and were housed in a room with appropriate temperature and humidity control, with a 12-h light / dark cycle, free access to food and water, and fed with standard laboratory diet (Cat. No. 1010001, a product of Jiangsu Collaborative Pharmaceutical Bioengineering Co., Ltd.). Experiments were performed after one week of adaptation.

[0041] 2 Experimental strains

[0042] Lactobacillus johnsonii LJ-XR25 was inoculated into MRS liquid medium at a 2% inoculum and cultured anaerobically at 37°C for 24 h. Then, the culture was transferred into fresh MRS liquid medium and cultured under the same conditions for 24 h. The bacterial sludge was obtained by filtration in an anaerobic workstation and then washed and resuspended with 0.8.1M PBS (pH 7.2, containing 0.05% cysteine) to obtain a bacterial concentration of 5×10 8 CFU / mL bacterial suspension should be stored in a well-sealed freeze-dried bottle with a stopper and used on the same day.

[0043] 3 Animal grouping and treatment

[0044] After one week of adaptive feeding, 24 C57 / Bl6J mice were randomly assigned to cages, 6 mice per cage, and continued to be fed with a 60% fat high-fat diet (D12492, Research diets) for 10 weeks. Then, the mice were randomly divided into two groups, a high-fat diet group (HFD group) and a high-fat diet + LJ-XR25 gavage group (LJ-XR25 group), with 2 cages of mice in each group. Among them, each mouse in the HFD group was gavaged with 0.2 mL of normal saline per day, and each mouse in the LJ-XR25 group was gavaged with 0.2 mL of LJ-XR25 5×10 8 CFU / mL bacterial suspension, once a day; both groups continued to be fed a high-fat diet and had free access to food and water during the experiment, which lasted for 4 weeks.

[0045] At the end of the experiment, the mice were killed by cervical dislocation. The heart, liver, spleen, lung, kidney, blood, ileum, cecum, and colon were removed and immediately placed in liquid nitrogen and stored at -80°C for further analysis. The subcutaneous and visceral fat deposits were precisely dissected and weighed.

[0046] 4. Detection indicators

[0047] 4.1 Determination of serum and liver AST, ALT, GSH, HDL, etc.

[0048] Whole blood was centrifuged at 2500 rpm / min for 10 min to collect serum, and the test was performed according to the manufacturer's kit (Nanjing Jiancheng Bioengineering Institute).

[0049] 4.2 Pathological examination of mouse liver and adipose tissue

[0050] Mouse scrotum and epididymis tissues were fixed in formalin for 24 hours, dehydrated, embedded, stained, and finally imaged under a microscope.

[0051] 4.3 Detection of gene expression levels related to fat metabolism in mouse liver

[0052] The liver was taken out from the -80℃ ultra-low temperature refrigerator, and 20 mg of tissue was weighed to extract total RNA. The RNA was reverse transcribed into cDNA using a reverse transcription kit, and cDNA was used as a template for fluorescence quantitative PCR amplification. β-actin was used as an internal reference and 2 -ΔΔCT The mNRA expression of related genes was calculated by this method.

[0053] The primer sequences are as follows

[0054] Gene Upstream primer Downstream primer Ppara TTTCACAAGTGCCTGTCTGTCG TCTTCAGGTAGGCTTCGTGGAT Cyp7a1 GCTAAGGAGGACTTCACTCTACACC TGGTCTTTGCTTTCCCACTTTC Cpt1a GCCTCTATGTGGTGTCCAAGTATC CACCATAGCCGTCATCAGCAA SCD-1 GTTAGCACCTTCTTGCGATACACT GTGAAGTTGATGTGCCAGCG FAS CTGCCTCTGGTGCTTGCT ACCCGCCTCCTCAGCTTT PPAR-γ GACCACTCGCATTCCTTTGA CCACAGACTCGGCACTCAAT GAPDH CCTCGTCCCGTAGACAAAATG TGAGGTCAATGAAGGGGTCGT

[0055] Note: PPAR-α: peroxisome proliferator-activated receptor α; PPAR-γ: peroxisome proliferator-activated receptor gamma; CYP7A1: cholesterol 7-alpha hydroxylase; CPT-1: carnitine palmitoyltransferase 1; FAS: fatty acid synthase; SCD-1: stearoyl-CoA desaturase-1; GAPDH: 3-phosphate dehydrogenase.

[0056] 5 Statistical methods

[0057] Prism software was used to measure the data for collation and statistical analysis, and the data were expressed as mean ± standard deviation (xˉ±s). Wilcoxon test was used for significance analysis. P<0.05 indicated statistical significance, and P<0.01 indicated significant statistical difference. For quantitative experiments, three replicates were set up unless otherwise specified, and the results were averaged.

[0058] 6 Results

[0059] 6.1 Effect of Lactobacillus johnsonii LJ-XR25 on the body weight of obese mice

[0060] Compared with the HFD group, the body weight of mice treated with LJ-XR25 for 4 weeks decreased significantly (p<0.05) by about 2.80 g, with a decrease rate of 5.68% ( Figure 1a, b). Weighing subcutaneous and visceral fat revealed that the LJ-XR25 group had significantly lower fat than the HFD group in terms of inguinal subcutaneous, epididymal, and perirenal fat ( Figure 1 ce); HE staining of liver and epididymal fat revealed that fatty degeneration in the liver of mice treated with XR25 was reduced and the diameter of fat droplets was reduced ( Figure 2 The above results show that LJ-XR25 can significantly reduce the fat content of mice fed a high-fat diet and has a significant inhibitory effect on the weight gain of mice fed a high-fat diet.

[0061] 6.2 Effects of Lactobacillus johnsonii LJ-XR25 on fat metabolism-related factors in obese mice

[0062] Figure 3 The results of lipid metabolism-related factors in serum, muscle and liver of the two groups of mice after the experiment showed that compared with the HFD group, the TC and TG in the serum and liver of the LJ-XR25 group mice were significantly decreased (p<0.01), the HDL in the serum was significantly decreased (p<0.01), while the LDL did not change significantly (p>0.05); the GSH level in the liver tissue was significantly increased (p<0.01). This result shows that Lactobacillus johnsonii LJ-XR25 can improve the hyperlipidemia symptoms of mice fed a high-fat diet after oral administration, and has the ability to improve the liver's antioxidant capacity and the ability to transport phospholipids and cholesterol and eliminate cholesterol in peripheral blood vessels.

[0063] Figure 4 The results of QPCR detection of gene expression showed that compared with the HFD group, the lipolysis genes PPAR-α and CPT-1 in the liver of the LJ-XR25 group mice did not change significantly, but CYP7A1 increased significantly (p<0.05), and the three fat synthesis genes PPAR-γ, SCD-1 and FAS were significantly downregulated (p<0.01). This result shows that after oral administration of Lactobacillus johnsonii LJ-XR25, it may mainly inhibit the fat synthesis in the liver of mice, and ultimately reduce the total amount of fat, so as to achieve the purpose of controlling or losing weight.

[0064] 6.3 Effects of Lactobacillus johnsonii LJ-XR25 on the intestinal flora structure of obese mice

[0065] Figure 5 The results of the changes in the intestinal flora structure of the two groups are shown in Figure 2. Figure 5 a) and PCOA( Figure 5 b) It was found that the fecal flora of mice in the LJ-XR25 group was significantly different from that in the HFD group, and the diversity was increased. This result shows that LJ-XR25 can restore the intestinal flora structure disorder caused by high-fat diet to normal. LEfSc analysis ( Figure 5cf) results showed that the abundance of Faecalibaculum rodentium, which is negatively correlated with obesity, was significantly reduced in the LJ-XR25 group, while the abundance of LJ-XR25 was significantly increased. The above results show that the LJ-XR25 provided by the present invention can colonize in the intestines of mice fed a high-fat diet, and can repair the flora disorder caused by a high-fat diet and restore the intestinal ecological balance.

[0066] 7 Conclusion

[0067] The Lactobacillus johnsonii LJ-XR25 provided by the present invention can significantly reduce the weight of obese mouse models, and significantly reduce the fat content in the groin, perirenal and epididymis of obese mice; it can effectively reduce the blood sugar, triglycerides and free fatty acids and fatty liver AST and ALT levels of obese mice, improve the hyperlipidemia symptoms of mice on a high-fat diet, improve the antioxidant capacity of the liver and the ability to transport phospholipids and cholesterol, and eliminate cholesterol in peripheral blood vessels, and achieve the function of regulating lipid metabolism; at the same time, Lactobacillus johnsonii LJ-XR25 can be colonized in the intestine, increase the diversity of intestinal flora, and achieve the effect of repairing the intestinal flora disorder caused by a high-fat diet, and restore the ecological balance of the intestine. The Lactobacillus johnsonii LJ-XR25 provided by the present invention can be effectively used to prepare foods, medicines, microbial preparations or feed additives for preventing and / or alleviating and / or improving and / or treating obesity, and has broad application value and practical significance.

[0068] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit the same. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that the technical solutions described in the aforementioned embodiments may still be modified, or some of the technical features may be replaced by equivalents. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A Lactobacillus johnsonii LJ-XR25, characterized in that The Lactobacillus johnsonii LJ-XR25 belongs to the genus Lactobacillus and has been deposited in the Guangdong Provincial Microbiological Collection Center on August 15, 2024, with a deposit number of GDMCC NO:65011.

2. A microbial preparation containing Lactobacillus johnsonii LJ-XR25.

3. The microbial preparation according to claim 2, characterized in that The viable count of Lactobacillus johnsonii LJ-XR25 in the microbial preparation is not less than 1×10 9 CFU / g.

4. Use of Lactobacillus johnsonii LJ-XR25 in the preparation of products for preventing and / or improving and / or alleviating and / or treating obesity.

5. Application of Lactobacillus johnsonii LJ-XR25 in the preparation of products for inhibiting weight gain.

6. Use of Lactobacillus johnsonii LJ-XR25 in the preparation of products that inhibit lipid production genes FASN and / or PPAR-R and / or SCD-1.

7. Application of Lactobacillus johnsonii LJ-XR25 in the preparation of products for regulating intestinal symbiotic flora.

8. The use according to any one of claims 4 to 7, characterized in that: The products include but are not limited to microbial preparations, ordinary foods, special foods, medicines, and feed additives.

9. The use according to any one of claims 4 to 7, characterized in that: The product also contains auxiliary materials, which include but are not limited to excipients or additives.

10. The use according to any one of claims 4 to 7, characterized in that: The viable count of Lactobacillus johnsonii LJ-XR25 in the product is not less than 1×10 9 CFU / g.

Citation Information

Patent Citations

  • Lactobacillus johnsonii and application thereof

    CN113215029A

  • Lactobacillus johnsonii LS04 and application of lactobacillus johnsonii LS04 in preparation of fat-reducing and weight-losing products

    CN115895971A

  • Lactobacillus johnsonii and application thereof

    CN117821317A

  • Lactobacillus johnsonii hfi 108 having blood cholesterol level lowering and Anti-obesity activity

    KR1020100010015A

  • Fuel cell system and thermal management control method thereof

    KR1020240025298A

Cited By

  • Traditional Chinese medicine compound essential oil of ludwigia odorifera and application thereof in preparation of products for preventing and treating obesity

    CN119679910A

  • Lactobacillus johnsonii and application of lactobacillus johnsonii in preparation of anti-inflammatory products, fat-reducing products or blood sugar-reducing products

    CN120738055A

  • Composition helpful for controlling in-vivo fat and application thereof

    CN120899770A

  • A composition for aiding in the control of body fat and uses thereof

    CN120899770B